A Double-Blind, Placebo-controlled Parallel Group, Phase II Dose-Ranging Study of Nebulized Amikacin Delivered Via the Pulmonary Drug Delivery System (PDDS) in Ventilated Patients With Nosocomial Pneumonia Due to Gram Negative Organisms.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2012
At a glance
- Drugs Amikacin (Primary)
- Indications Gram-negative infections; Nosocomial pneumonia
- Focus Pharmacokinetics
- Sponsors Bayer
- 01 Feb 2012 Results published in Intensive Care Medicine.
- 08 Nov 2009 New trial record